[go: up one dir, main page]

WO2009080764A3 - Administration orale ou nasale de composés comprenant des séquences d'acides aminés - Google Patents

Administration orale ou nasale de composés comprenant des séquences d'acides aminés Download PDF

Info

Publication number
WO2009080764A3
WO2009080764A3 PCT/EP2008/068053 EP2008068053W WO2009080764A3 WO 2009080764 A3 WO2009080764 A3 WO 2009080764A3 EP 2008068053 W EP2008068053 W EP 2008068053W WO 2009080764 A3 WO2009080764 A3 WO 2009080764A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
oral
nasal administration
amino acid
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/068053
Other languages
English (en)
Other versions
WO2009080764A2 (fr
Inventor
Hendricus Renerus Jacobus Mattheus Hoogenboom
Johannes Joseph Wilhelmus De Haard
Maria Gonzalez
Peter Vanlandschoot
Jan Terje Andersen
Gestuur Vidarsson
Edward Dolk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABYLNX NV
Original Assignee
ABYLNX NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ABYLNX NV filed Critical ABYLNX NV
Publication of WO2009080764A2 publication Critical patent/WO2009080764A2/fr
Publication of WO2009080764A3 publication Critical patent/WO2009080764A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des composés comprenant des séquences d'acides aminés tels que des domaines variables uniques pour une administration orale ou nasale et sur des compositions pharmaceutiques comprenant lesdits composés. Plus particulièrement, l'invention porte sur des composés dans lesquels la liaison à au moins l'un des antigènes ou épitopes choisis dans le groupe des transporteurs épithéliaux sert à augmenter la biodisponibilité du composé in vivo. La présente invention porte de plus sur divers procédés supplémentaires pour améliorer la biodisponibilité desdits composés de l'invention lors de l'utilisation d'une administration orale ou nasale.
PCT/EP2008/068053 2007-12-20 2008-12-19 Administration orale ou nasale de composés comprenant des séquences d'acides aminés Ceased WO2009080764A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1532007P 2007-12-20 2007-12-20
US61/015,320 2007-12-20
US5389208P 2008-05-16 2008-05-16
US61/053,892 2008-05-16

Publications (2)

Publication Number Publication Date
WO2009080764A2 WO2009080764A2 (fr) 2009-07-02
WO2009080764A3 true WO2009080764A3 (fr) 2010-06-03

Family

ID=40668459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/068053 Ceased WO2009080764A2 (fr) 2007-12-20 2008-12-19 Administration orale ou nasale de composés comprenant des séquences d'acides aminés

Country Status (1)

Country Link
WO (1) WO2009080764A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
ES2701649T3 (es) * 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
EP2275442A1 (fr) * 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Détection et visualisation du cycle cellulaire dans des cellules vivantes
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CN114949185A (zh) * 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
JP7530173B2 (ja) 2016-08-17 2024-08-07 エンテラ バイオ エルティーディー． 活性薬剤の経口投与のための製剤
KR20220054585A (ko) * 2019-08-02 2022-05-03 얀센 바이오테크 인코포레이티드 고분자 항체 수용체 표적화를 위한 재료 및 방법
AU2020335394A1 (en) * 2019-08-29 2022-03-24 National Institute For Biotechnology In The Negev Ltd. A single-domain antibody for targeting prostate specific membrane antigen (PSMA)
JP2023537470A (ja) 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
EP4225798A4 (fr) * 2020-10-12 2025-08-06 Janssen Biotech Inc Matières et procédés biosynthétiques pour le biotransport multidirectionnel
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
WO2024107885A1 (fr) * 2022-11-15 2024-05-23 Vanderbilt University Conjugués nanocorps-médicament et procédés de préparation associés
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
WO2024170756A1 (fr) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides se liant au récepteur fc néonatal
AR133188A1 (es) * 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005073383A2 (fr) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Proteines de fusion heterodimere de l'hormone-fc stimulant les follicules (fsh-fc) utiles dans le traitement de l'infertilite
US20070020192A1 (en) * 1995-01-17 2007-01-25 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20070087001A1 (en) * 2005-10-19 2007-04-19 Center For Molecular Medicine And Immunology Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
WO2007067597A2 (fr) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Procedes et compositions d'apport sans aiguille de partenaires de liaison
WO2007087289A2 (fr) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York ANTICORPS ANTI-FcRn UTILISÉS DANS LE TRAITEMENT D'ÉTATS AUTO/ALLO-IMMUNS
WO2008074868A1 (fr) * 2006-12-20 2008-06-26 Ablynx N.V. Administration par voie orale de polypeptides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020192A1 (en) * 1995-01-17 2007-01-25 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005073383A2 (fr) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Proteines de fusion heterodimere de l'hormone-fc stimulant les follicules (fsh-fc) utiles dans le traitement de l'infertilite
US20050186662A1 (en) * 2004-01-28 2005-08-25 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US20070087001A1 (en) * 2005-10-19 2007-04-19 Center For Molecular Medicine And Immunology Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
WO2007067597A2 (fr) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Procedes et compositions d'apport sans aiguille de partenaires de liaison
WO2007087289A2 (fr) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York ANTICORPS ANTI-FcRn UTILISÉS DANS LE TRAITEMENT D'ÉTATS AUTO/ALLO-IMMUNS
WO2008074868A1 (fr) * 2006-12-20 2008-06-26 Ablynx N.V. Administration par voie orale de polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE CHANG HOON ET AL: "Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, ACADEMIC PRESS, US, vol. 46, no. 3-4, 1 April 2007 (2007-04-01), pages 211 - 217, XP009105401, ISSN: 0885-4513 *

Also Published As

Publication number Publication date
WO2009080764A2 (fr) 2009-07-02

Similar Documents

Publication Publication Date Title
WO2009080764A3 (fr) Administration orale ou nasale de composés comprenant des séquences d'acides aminés
WO2009034119A8 (fr) Dérivés améliorés de l'amyline
EP3210625A3 (fr) Les peptides thérapeutiques comprenant la liaison aux anticorps polypeptide mhc de classe 1 série a (mica)
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2010065709A3 (fr) Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
WO2009061996A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (dec-205) humaine
WO2007100905A3 (fr) Conjugués de polymères contenant de l'acryloyloxyéthylphosphorylcholine et leur préparation
WO2010127856A8 (fr) Phénylurées et phénylamides substitués en tant que ligands du récepteur vanilloïde
WO2011124953A3 (fr) Compositions pharmaceutiques à libération contrôlée de tapentadol
WO2009064460A3 (fr) Systèmes de délivrance aux voies gastro-intestinales
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2006028936A3 (fr) Molecules heteromultimeriques
WO2012019165A3 (fr) Procédés d'inhibition de la fucosylation in vivo de protéines en utilisant des analogues du fucose
WO2010139808A3 (fr) Séquences d'acides aminés améliorées dirigées contre le virus respiratoire syncytial (rsv) humain et polypeptides les comprenant pour la prévention et/ou le traitement des infections de l'appareil respiratoire
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2009121039A3 (fr) Administration de compositions de benzodiazépine
WO2009067686A3 (fr) Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
WO2008017381A8 (fr) Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
WO2010055082A3 (fr) Nouvelle forme cristalline de malate de sunitinib
WO2005067893A3 (fr) Compositions pharmaceutiques contenant du midazolam dans une concentration elevee
TW200630336A (en) Novel compounds
WO2008034142A3 (fr) Synthèse, procédés d'utilisation et compositions de cycloalkylméthylamines
TW200621690A (en) Novel compounds
WO2007052023A3 (fr) Composes
WO2009064366A3 (fr) Procédés et compositions pour un marquage protéique à l'aide d'acide lipoïque ligases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863859

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08863859

Country of ref document: EP

Kind code of ref document: A2